Alteogen Inc.
196170
Clasificación en acciones
#1921
ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters,... ALTEOGEN Inc., a bio company, focuses on developing long-acting biobetters, proprietary antibody-drug conjugates, and antibody biosimilars. The company develops ALT-P1, a long-acting human growth hormone that is in the Phase IIa clinical trial; and ALT-Q2, a long-acting active form of coagulation factor VII for the treatment of hemophilia based on its NexP technology. It is also involved in the development of ALT-P7, a targeted breast/gastric cancer drug that is in the Phase I clinical trial; ALT-Q5, an antibody-drug conjugate (ADC) for the treatment of ovarian cancer based on its NexMab ADC technology; and ALT-LS2, a SC (subcutaneous) formulation of trastuzuamb for the treatment of breast and gastric cancer. The company has a strategic alliance with Kissei Pharmaceutical for the development of ALT-L9, a biosimilar of Eylea (Aflibercept) which is currently under Phase 1 trial; Cristalia for the development of ALT-L2, a biosimilar of Herceptin (Trastuzumab), a monoclonal antibody for the treatment of breast cancer, which is in the Phase II clinical trial; and Biogen Inc. to develop subcutaneous (SC) formulations of biologics utilizing ALT-B4. ALTEOGEN Inc. was founded in 2008 and is headquartered in Daejeon, South Korea.
Precio por acción
$159.04
Capitalización bursátil
$11.07B
Cambio (1 día)
-2.95%
Cambio (1 año)
-48.94%
País
KR
Comercio Alteogen Inc. (196170)
Categoría
Healthcare
Margen Operativo de Alteogen Inc. (196170)
Margen Operativo al October 2026 TTM: 47.16%
Según los informes financieros más recientes y el precio de las acciones de Alteogen Inc., el margen operativo actual (TTM) es 47.16%. Al final de 2023, el margen operativo era -10.09%.
Historial de Margen Operativo de Alteogen Inc. desde 2012 hasta 2026
Margen Operativo al final de cada año
| Año | Margen Operativo | Cambiar |
|---|---|---|
| 2026 (TTM) | 47.16% | 90.93% |
| 2024 | 24.70% | -344.80% |
| 2023 | -10.09% | -90.10% |
| 2022 | -101.97% | 160.06% |
| 2021 | -39.21% | 27,907.14% |
| 2020 | -0.14% | -98.18% |
| 2019 | -7.70% | -86.23% |
| 2018 | -55.90% | 9.61% |
| 2017 | -51.00% | -35.50% |
| 2016 | -79.07% | -3,117.94% |
| 2015 | 2.62% | -74.51% |
| 2014 | 10.28% | -62.39% |
| 2013 | 27.33% | -34.80% |
| 2012 | 41.92% | 0.00% |
Margen Operativo de empresas similares o competidoras
| Empresa | Margen Operativo | Diferencia de Margen Operativo | País |
|---|---|---|---|
| 38.59% | -99.18% |
US
|
|
| -149.01% | -103.16% |
US
|
|
| 25.57% | -99.46% |
AU
|
|
| 0.00% | - |
CH
|
|
| 28.81% | -99.39% |
NL
|
¿Qué es el Margen Operativo de una empresa?
El Margen Operativo es un indicador clave para evaluar la rentabilidad de una empresa. Un margen operativo más alto suele ser mejor, ya que indica que una empresa puede vender sus productos o servicios por mucho más de lo que cuestan producirlos. Se calcula dividiendo las ganancias de la empresa entre sus ingresos.